Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong Hyun | - |
dc.contributor.author | Son, Sang Wook | - |
dc.contributor.author | Jeong, Ki-Heon | - |
dc.contributor.author | Ahn, Jiyoung | - |
dc.contributor.author | Lee, Eun-So | - |
dc.contributor.author | Kim, Il-Hwan | - |
dc.contributor.author | Ha Lee, Un | - |
dc.contributor.author | Park, Hai-Jin | - |
dc.contributor.author | Ko, Joo Yeon | - |
dc.contributor.author | Kim, Byung-Soo | - |
dc.contributor.author | Kim, Jin Ju | - |
dc.contributor.author | Rashid, Javed | - |
dc.contributor.author | Kim, Kwang Joong | - |
dc.date.accessioned | 2023-06-01T07:03:53Z | - |
dc.date.available | 2023-06-01T07:03:53Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1013-9087 | - |
dc.identifier.issn | 2005-3894 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185857 | - |
dc.description.abstract | Background: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations.Objective: To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis.Methods: This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM.Results: Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00-80.00) and 12.40 (range 2.70-39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (p=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted.Conclusion: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registra tion number (clinicaltrials.gov: NCT03099083). | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN DERMATOLOGICAL ASSOC | - |
dc.title | Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study) | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5021/ad.22.041 | - |
dc.identifier.scopusid | 2-s2.0-85151081275 | - |
dc.identifier.wosid | 000970753900004 | - |
dc.identifier.bibliographicCitation | ANNALS OF DERMATOLOGY, v.35, no.2, pp 107 - 115 | - |
dc.citation.title | ANNALS OF DERMATOLOGY | - |
dc.citation.volume | 35 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 107 | - |
dc.citation.endPage | 115 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002942958 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | REPORTED OUTCOMES | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Adalimumab | - |
dc.subject.keywordAuthor | Health-related quality of life | - |
dc.subject.keywordAuthor | Psoriasis | - |
dc.identifier.url | https://anndermatol.org/DOIx.php?id=10.5021/ad.22.041 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.